At a glance
ClinicalIndex Comparison RecordPhase 3Active· 1,620 enrolled
Drug / intervention
VeraCeptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept®, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability
In Brief
A Phase 3 clinical trial evaluating VeraCept for Women at Risk for Pregnancy. Active but no longer recruiting, targeting 1,620 participants across 41 sites.
Detailed Summary
To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWomen at Risk for Pregnancy
CountriesUnited States
CollaboratorsSyneos Health
Timeline
Phase 3Active
201920202021202220232024202520262027
First PostedAug 2018
Enrollment StartAug 2018
Primary CompletionSep 2022
TodayJul 2026
Study CompletionSep 2027
First PostedAug 16, 2018
Enrollment StartAug 22, 2018
Primary CompletionSep 22, 2022
Study CompletionSep 22, 2027
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.9 years ago
Interventions
VeraCeptdrug
VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method